UCSC Human Gene Sorter
 
genome assembly search
sort by display output 
#
Name
VisiGene
BLASTP
E-Value
Genome Position
Description
1S100A8n/a
n/a
n/a
n/a
2e-49chr1 153,390,552S100 calcium binding protein A8, transcript variant 4 (from RefSeq NM_002964.5)
2SPRR3n/a
n/a
n/a
n/a
n/achr1 153,002,802small proline rich protein 3, transcript variant 2 (from RefSeq NM_001097589.2)
3KRT6An/a
n/a
n/a
n/a
n/achr12 52,490,216keratin 6A (from RefSeq NM_005554.4)
4CRNNn/a
    
    
     
0.0000001chr1 152,411,753cornulin (from RefSeq NM_016190.3)
5KRT4n/a
n/a
n/a
n/a
n/achr12 52,810,332keratin 4 (from RefSeq NM_002272.4)
6RHCG32259
n/a
n/a
n/a
n/achr15 89,483,995Rh family C glycoprotein, transcript variant 1 (from RefSeq NM_016321.3)
7SPRR2An/a
    
    
     
n/achr1 153,056,816small proline rich protein 2A (from RefSeq NM_005988.3)
8CSTAn/a
    
    
     
n/achr3 122,333,608cystatin A (from RefSeq NM_005213.4)
9SPRR1Bn/a
n/a
n/a
n/a
n/achr1 153,032,051small proline rich protein 1B (from RefSeq NM_003125.3)
10S100A14n/a
n/a
n/a
n/a
n/achr1 153,615,290S100 calcium binding protein A14 (from RefSeq NM_020672.3)
11S100A12n/a
n/a
n/a
n/a
0.0000000002chr1 153,374,666S100 calcium binding protein A12 (from RefSeq NM_005621.2)
12FABP5P7n/a
n/a
n/a
n/a
n/achr11 59,781,520fatty acid binding protein 5 pseudogene 7 (from HGNC FABP5P7)
13FCER1Gn/a
n/a
n/a
n/a
n/achr1 161,217,270Fc epsilon receptor Ig (from RefSeq NM_004106.2)
14CNFNn/a
n/a
n/a
n/a
n/achr19 42,388,658cornifelin (from RefSeq NM_032488.4)
15TGM3n/a
    
    
     
n/achr20 2,318,540transglutaminase 3 (from RefSeq NM_003245.4)
16ENSG00000286022n/a
    
    
     
n/achr20 2,274,193  Name=Ca(2+); Xref=ChEBI:CHEBI:29108;    Evidence=;  Note=Binds 1 Ca(2+) ion per subunit. ; (from UniProt A0A494C0J7)
17IGHG3n/a
n/a
n/a
n/a
n/achr14 105,767,954immunoglobulin heavy constant gamma 3 (G3m marker) (from HGNC IGHG3)
18ANXA1n/a
n/a
n/a
n/a
n/achr9 73,161,129annexin A1 (from RefSeq NM_000700.3)
19GJB2n/a
    
    
     
n/achr13 20,190,204gap junction protein beta 2 (from RefSeq NM_004004.6)
20CST7n/a
n/a
n/a
n/a
n/achr20 24,954,598cystatin F (from RefSeq NM_003650.4)
21SERPINB3n/a
n/a
n/a
n/a
n/achr18 63,658,545serpin family B member 3 (from RefSeq NM_006919.3)
22SELLn/a
n/a
n/a
n/a
n/achr1 169,701,143selectin L, transcript variant 2 (from RefSeq NR_029467.2)
23MUC21n/a
    
    
     
n/achr6 30,986,810mucin 21, cell surface associated, transcript variant 2 (from RefSeq NR_130720.3)
24RAC2n/a
n/a
n/a
n/a
n/achr22 37,234,769Rac family small GTPase 2 (from RefSeq NM_002872.5)
25PI3n/a
    
    
     
n/achr20 45,175,723peptidase inhibitor 3 (from RefSeq NM_002638.4)
26CRABP2n/a
n/a
n/a
n/a
n/achr1 156,702,594cellular retinoic acid binding protein 2, transcript variant 1 (from RefSeq NM_001878.4)
27IGHG4n/a
n/a
n/a
n/a
n/achr14 105,623,286Constant region of immunoglobulin heavy chains.  Immunoglobulins, also known as antibodies, are membrane-bound or  secreted glycoproteins produced by B lymphocytes. In the recognition  phase of humoral immunity, the membrane-bound immunoglobulins serve as  receptors which, upon binding of a specific antigen, trigger the clonal  expansion and differentiation of B lymphocytes into immunoglobulins-  secreting plasma cells. Secreted immunoglobulins mediate the effector  phase of humoral immunity, which results in the elimination of bound  antigens (PubMed:22158414, PubMed:20176268). The antigen binding site  is formed by the variable domain of one heavy chain, together with that  of its associated light chain. Thus, each immunoglobulin has two  antigen binding sites with remarkable affinity for a particular  antigen. The variable domains are assembled by a process called V-(D)-J  rearrangement and can then be subjected to somatic hypermutations  which, after exposure to antigen and selection, allow affinity  maturation for a particular antigen (PubMed:17576170, PubMed:20176268). (from UniProt P01861)
28GPSM3n/a
n/a
n/a
n/a
n/achr6 32,191,704G protein signaling modulator 3, transcript variant 1 (from RefSeq NM_001276501.2)
29ECM1n/a
n/a
n/a
n/a
n/achr1 150,510,949extracellular matrix protein 1, transcript variant 1 (from RefSeq NM_004425.4)
30CALML3n/a
n/a
n/a
n/a
n/achr10 5,525,866calmodulin like 3 (from RefSeq NM_005185.4)
31LAPTM5n/a
    
    
     
n/achr1 30,745,121lysosomal protein transmembrane 5 (from RefSeq NM_006762.3)
32FCGR3Bn/a
n/a
n/a
n/a
n/achr1 161,627,186Fc gamma receptor IIIb, transcript variant 4 (from RefSeq NM_001271036.2)
33HMOX1n/a
n/a
n/a
n/a
n/achr22 35,387,651heme oxygenase 1 (from RefSeq NM_002133.3)
34SLC11A1n/a
n/a
n/a
n/a
n/achr2 218,389,583solute carrier family 11 member 1 (from RefSeq NM_000578.4)
35S100A2n/a
n/a
n/a
n/a
0.000002chr1 153,563,476S100 calcium binding protein A2, transcript variant 1 (from RefSeq NM_005978.4)
36IGHG2n/a
    
    
     
n/achr14 105,642,174Constant region of immunoglobulin heavy chains.  Immunoglobulins, also known as antibodies, are membrane-bound or  secreted glycoproteins produced by B lymphocytes. In the recognition  phase of humoral immunity, the membrane-bound immunoglobulins serve as  receptors which, upon binding of a specific antigen, trigger the clonal  expansion and differentiation of B lymphocytes into immunoglobulins-  secreting plasma cells. Secreted immunoglobulins mediate the effector  phase of humoral immunity, which results in the elimination of bound  antigens (PubMed:22158414, PubMed:20176268). The antigen binding site  is formed by the variable domain of one heavy chain, together with that  of its associated light chain. Thus, each immunoglobulin has two  antigen binding sites with remarkable affinity for a particular  antigen. The variable domains are assembled by a process called V-(D)-J  rearrangement and can then be subjected to somatic hypermutations  which, after exposure to antigen and selection, allow affinity  maturation for a particular antigen (PubMed:17576170, PubMed:20176268). (from UniProt P01859)
37COPDA1n/a
n/a
n/a
n/a
n/achr14 105,648,490COPDA1 (from geneSymbol)
38FCN1n/a
n/a
n/a
n/a
n/achr9 134,910,572ficolin 1 (from RefSeq NM_002003.5)
39NCF4n/a
n/a
n/a
n/a
n/achr22 36,869,510neutrophil cytosolic factor 4, transcript variant 1 (from RefSeq NM_000631.5)
40FGRn/a
n/a
n/a
n/a
n/achr1 27,623,624FGR proto-oncogene, Src family tyrosine kinase, transcript variant 1 (from RefSeq NM_005248.3)
41EMP1n/a
n/a
n/a
n/a
n/achr12 13,208,333epithelial membrane protein 1 (from RefSeq NM_001423.3)
42ALPL22304
n/a
n/a
n/a
n/achr1 21,543,916alkaline phosphatase, biomineralization associated, transcript variant 6 (from RefSeq NM_001369805.2)
43SERPINB1n/a
n/a
n/a
n/a
n/achr6 2,837,097serpin family B member 1, transcript variant 3 (from RefSeq NR_073112.2)
44CD53n/a
n/a
n/a
n/a
n/achr1 110,886,535CD53 molecule, transcript variant 3 (from RefSeq NM_001320638.2)
45DEFA3n/a
n/a
n/a
n/a
n/achr8 7,017,083defensin alpha 3 (from RefSeq NM_005217.4)
46ITGB2n/a
n/a
n/a
n/a
n/achr21 44,903,426integrin subunit beta 2, transcript variant 3 (from RefSeq NM_001303238.2)
47HCLS1n/a
n/a
n/a
n/a
n/achr3 121,646,151hematopoietic cell-specific Lyn substrate 1, transcript variant 1 (from RefSeq NM_005335.6)
48MNDAn/a
    
    
     
n/achr1 158,840,426myeloid cell nuclear differentiation antigen (from RefSeq NM_002432.3)
49VSIRn/a
n/a
n/a
n/a
n/achr10 71,760,538V-set immunoregulatory receptor (from RefSeq NM_022153.2)
50TNFRSF1Bn/a
n/a
n/a
n/a
n/achr1 12,188,105TNF receptor superfamily member 1B (from RefSeq NM_001066.3)